# Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

> **NCT07680569** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Kaohsiung Medical University Chung-Ho Memorial Hospital** · enrollment: 40 (estimated)

## Conditions studied

- GC/GEJC

## Interventions

- **BIOLOGICAL:** Zolbetuximab
- **DRUG:** Oxaliplatin + 5-Fluorouracil/Leucovorin
- **DRUG:** CAPOX (oxaliplatin/capecitabine)

## Key facts

- **NCT ID:** NCT07680569
- **Lead sponsor:** Kaohsiung Medical University Chung-Ho Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680569, "Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07680569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*